Management at Medtronic (MDT) Cautiously Optimistic End-Markets Stabilizing

September 20, 2012 12:43 PM EDT Send to a Friend
Get Alerts MDT Hot Sheet
Price: $66.56 +1.45%

Rating Summary:
    17 Buy, 14 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 28 | New: 14
Trade MDT Now!
Join SI Premium – FREE
Recently analysts at UBS met with the Gary Ellis (CEO) and Jeff Warren (VP) at medical technology company Medtronic (NYSE: MDT). The executives were cautiously optimistic that underlying core end-markets are stabilizing, though visibility is imperfect, particularly in Spine.

Analysts said there was ‚Äúreasonable plausibility‚ÄĚ that guidance could be lifted next quarter if end-markets continue to cooperate.

Analyst also said that the Spine market looked like it was improving, and the ICD market was stabilizing.

UBS raises their price target on Medtronic to $48 from $46 and reiterated their Buy rating.

For an analyst ratings summary and ratings history on Medtronic, Inc. click here. For more ratings news on Medtronic, Inc. click here.

Shares of Medtronic, Inc. closed at $42.83 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

UBS

Add Your Comment